Algernon Pharmaceuticals Inc (QB) (AGNPF) Quote

Could This Stock Be the Next Bellus Cough Treatment?

https://www.streetwisereports.com/article/2024/07/17/could-this-stock-be-the-next-bellus-cough-treatment.html?utm_source=AGN-CNX

With all of the reverse splits .. my initial 50,000 shares is now 2,000. Lol go figure todays volume.

Looks like everyone split … 1,000 shares traded on some pretty good news

Study Showing 93% Cough Suppression with Ifenprodil

https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Reports-Results-of-Study-Showing-93-Cough-Suppression-with-Ifenprodil?id=446850

2,083,333 Units Per this Filing

https://webfiles.thecse.com/Algernon_CSE_Form_9_-_Juy_2024.pdf?xwI_B_aF3yzpRKAETnDXGgVEQpZBtyNc

Algernon Pharmaceuticals Announces Private Placement

https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Announces-Private-Placement?id=446532

gross proceeds of $250,000 (the “Offering”) of units (the “Units”) at an issue price of $0.12 per Unit

And thats CAD not USD so that $0.088 $AGNPF
on roughly 2,083,784 more diluted shares

Outstanding: 21,940,779 for July 10, 2024

Monthly 5th Report

https://webfiles.thecse.com/6._Algernon_-_CSE_Form_7_-_June_2024.pdf?75v3v4P.m.qiZNOTcs14RpT7cYj_RqOU

Thank you,
It’s a p1 ..
It’s over..
Let’s go P2..

Dr Heijden did the presentation about CHDR at the Psychedelic conference,,,

https://www.icpr-conference.com/speakers/katelijne-van-der-heijden

Seems the Defense Authorization bill has support for research using these drugs for PTSD and "wounds of war". TBA?
The Netherlands is also doing research along with Arizona, Texas and Oregon and more.
Come on Chris, present our research, tell us how it went and try to get us involved with this new funding...JMHFO...GLTA...

https://www.youtube.com/shorts/8b50ODFdMEY

Anyone have presentation?

Outstanding: 21,940,779 for June 6, 2024

Monthly 5th Report

https://webfiles.thecse.com/5._Algernon_-_CSE_Form_7_-_May_2024.pdf?P_P1hgWsY8Cb0IuHXny8OiFIIn_NDM5g

AGN presentation to CHDR later this week. Sure hope we can finally see some real interesting news...GLTA...

Doubled the $$$’s in 3 mo’s…gonna rocket!!!$$$

Insiders look to be Adding Shares

https://ceo.ca/agn

Like the action

NOTICE OF PROPOSED RESTRICTED SHARE UNIT (“RSU”) GRANT OR AMENDMENT

https://webfiles.thecse.com/CSE-Form-11-Notice-of-Proposed-RSUs_-_May_2024.pdf?vrVtJyueWiaIaZ1W3q33kPWkymhn1Uba

Algernon Pharmaceuticals Engages ICP Securities Inc. for Automated Market Making Services

https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Engages-ICP-Securities-Inc-for-Automated-Market-Making-Services?id=441221

Nice volume today

Outstanding: 21,840,722 for May 3, 2024

Monthly 5th Report

https://webfiles.thecse.com/4._Algernon_-_CSE_Form_7_-_April_2024.pdf?qaY9FopqdvCRcwssqB4AcLx7jW9LSh5C

200,000 commons to Maxim Group LLC for finding and Closing the Deal with Seyltx, Inc.

MDA filed today

https://webfiles.thecse.com/Algernon_-_MDA_-_February_29_2024.pdf?.kcXKKzsfZ43UIXaVuoDeMZgpfvFHMMH

Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024

https://www.otcmarkets.com/stock/AGNPF/news/Algernon-NeuroScience-and-the-Centre-for-Human-Drug-Research-to-Present-DMT-Phase-1-Stroke-Clinical-Data-at-the-Interdis?id=437889

Q&A and Webinar

Here is the link to the recording from last week’s webinar:

Christopher J. Moreau to Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar on April 16th, 2024

https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-CEO-Christopher-J-Moreau-to-Be-Featured-on-Radius-Researchs-Pitch-Deep-Dive-and-QA-Webinar-on-A?id=436475

Outstanding: 21,640,762 for April 4, 2024

Monthly 5th Report

https://webfiles.thecse.com/Algernon_-_CSE_Form_7_-_March_2024.pdf?Is_B3LCsJTGbo_e6ku57Z2tafpM1IKDQ

Is algernon neuro a traded stock by itself.

So no treatment for schemic stroke..
They do minimal things and then wait to see how bad the CNS was damaged..
Than try to rebuild what is lost..


When our drug roves itself..
It will need to be purchased everywhere
Stroke victims have access to treatment.. as the sooner you treat the better..

Our drug will not wait for patients .. caregivers will have to stick it..
Every ambulance, every hospital.. perhaps even every urgent care with me..

Depending on test for type of stroke and Pharma delivery system.. this could be like
Overdose or allergy med.. where they encourage everyone to have..
Depends on stroke test and safety of drug..
Micro dose DMT should be very safe..

That is worldwide in an aging population with increasing cardio system weakness..


$2million in bank.. if they can find clinical partner to share development cost with..
We are very blessed to be here

Neuroplasticity, dendritic spines, 1hr 40mins. He sites many papers, mostly in mouse/rat trials, in this presentation where neuroplasticity is observed, but it seems that the AGN 'microdosing for Stroke' concept is unique.



Yes, the when and where type of data for the clinical trials could be announced soon. Maybe Oregon where it's legal for research?
I've held this long already and will hold through the finish...
...GLTA...

The valuations are going to skyrocket on a positive phase 2a

I had found this presentation a long time ago. Finally found it again and it is a great video including neuroplasticity.

Sure great to see this all finally progressing.

“Investigating neuroplasticity in a clinical setting, as a potential new treatment approach for ischemic stroke patients, is a new and promising area of research,” said Christopher J. Moreau CEO of Algernon. “Algernon is a global leader in this important area of research, and we look forward to further advancing the stroke program through our planned Phase 2a DMT Stroke study.”

Phase 2a Stroke Study Design

Subjects with a confirmed diagnosis of ischemic stroke will be randomized in blinded fashion to receive either DMT or placebo. The primary outcome measure of the study will be safety, and information will be gained on measures of efficacy including preservation of brain tissue, motor recovery, depression and numerous biomarkers linked to the pathophysiology of stroke.

The veteran community has discussed TBI and PTSD issues and treatments involving Psycs. This group may also be a area of recruitment for future stroke/TBI research. There are already a few PTSD studies...

...GLTA...

Algernon going to move forward with 40 patient phase 2 for isechemic stroke.

Is there a Stroke Victim advocacy group which could help cover costs?

Can’t wait for results! 6 days of treatment..
40 patients.. normally a clinical trial takes forever..

How common is an ischemic stroke?

Strokes are very common. Worldwide, strokes rank second among the top causes of death. In the United States, they rank fifth. Strokes are also one of the leading causes of disability worldwide. Ischemic strokes make up about 85% of all strokes.

No shortage of need..

Stroke statistics
In 2021, 1 in 6 deaths from cardiovascular disease was due to stroke.1
Every 40 seconds, someone in the United States has a stroke.2 Every 3 minutes and 14 seconds, someone dies of stroke.1
Every year, more than 795,000 people in the United States have a stroke. About 610,000 of these are first or new strokes.2
About 185,000 strokes—nearly 1 in 4—are in people who have had a previous stroke.2
About 87% of all strokes are ischemic strokes, in which blood flow to the brain is blocked.2
Stroke-related costs in the United States came to nearly $56.5 billion between 2018 and 2019.2 This total includes the cost of health care services, medicines to treat stroke, and missed days of work.
Stroke is a leading cause of serious long-term disability.2 Stroke reduces mobility in more than half of stroke survivors age 65 and older.2

I think the goal will be to administer the first sub psych dose of DMT immediately after diagnosis..

A positive phase 2a.. would be a very large step for algernon

“Investigating neuroplasticity in a clinical setting, as a potential new treatment approach for ischemic stroke patients, is a new and promising area of research,

Most medicines may be cross scripted..
When DMT becomes available for stroke..
I imagine there will be many interested in other illnesses of the CNS for DMT help

Patience and faith in character rewarded!
Great job Chris and algernon

Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position

https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Announces-Closing-of-the-Acquisition-of-its-Chronic-Cough-Research-Program-by-US-Based-Seyltx-f?id=435013

https://stockhouse.com/companies/bullboard/agnpf/algernon-pharmaceuticals-inc?postid=35357630

117 Days counting Today from Nov 22nd

90 days from Nov 22,23
Dec
Jan
Feb
……

https://www.algernonpharmaceuticals.com/investors/news-events/news-releases/detail/192/algernon-pharmaceuticals-announces-loi-for-the-acquisition

Positive trading..
Deal closed maybe ?
Time running out to buy cheap?

Outstanding: 21,640,762 posted March 8, 2024

Monthly 5th Report

https://webfiles.thecse.com/2._Algernon_-_CSE_Form_7_-_February_2024.pdf?xL6dHIb_J8X9xx9tubyGTsjxO5yHy44W

Statement of Executive Compensation – Venture Issuers (for financial year ended August 31, 2023)

Posted Tuesday

https://sedar-filings-backup.thecse.com/00037722/2403061442375471.pdf

Thanks Shell,

This was known. Let hope he doesn’t dilute further. If everything goes right according to their previous news releases they wouldn’t need any cash infusions for a while which is good sign. I am hopeful for issuance of new patents etc.

Outstanding: 21,640,762 posted February 8, 2024

Monthly 5th Report for January filed today

https://webfiles.thecse.com/1._Algernon_-_CSE_Form_7_-_January_2024.pdf?vo61Q.9_pMwV5o_dI3dUQifkB4N2s71C

January 30th, 2024 this happened
Additionally, the Company granted 1,625,000 restricted share units (“RSU”) pursuant to its RSU Plan to executives and directors of the Company and 100,000 stock options, exercisable at $0.075 for two years from the date of grant, to a consultant of the Company. The RSUs and stock options vested on the grant date.

Microdose DMT for TBI too. There are Veterans organizations interested and discussions of are widely supported for 'shroom therapy' of PTSD... Proof of therapeutic benefits for stroke, etc.?.
...GLTA...

Agreed
Think this one is not going to have a lot of resistance

You are right about 90 days which should be by Feb 22/24.

https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Announces-LOI-for-the-Acquisition-of-its-Chronic-Cough-Research-Program-by-US-Based-Seyltx-for-?id=422342

I read it about it. However, I can’t find the news.

Can you post here the link for the news, please?

Thanks.

They have received two notice of granting two different patents from China within two months which is fast, unusual and excellent.
———

Algernon
Pharmaceuticals
Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat
NASH and NAFLD
Algernon Pharmaceuticals
Nov. 30, 2023 7:00 AM ET • 2 min read
———

Algernon
Pharmaceuticals
Receives Notice of
Intention to Grant from
Chinese Patent Office for Repirinast to Treat
CKD
Algernon Pharmaceuticals
Jan. 31, 2024 7:00 AM ET • 2 min read